Second primary malignancies in patients treated for gastric mucosa-associated lymphoid tissue lymphoma. - Université Toulouse 3 Accéder directement au contenu
Article Dans Une Revue Leukemia & lymphoma Année : 2017

Second primary malignancies in patients treated for gastric mucosa-associated lymphoid tissue lymphoma.

Résumé

To assess the risk of second primary malignancy (SPM) in patients with gastric mucosa-associated lymphoid tissue (MALT) Lymphoma (GML), we included 175 patients with GML in the present study. The incidence of SPM in the general population, used for reference, was determined from the French network of cancer registries. During the 1442.9 patient-years of follow-up, 29 patients were diagnosed with incident SPM, including five patients diagnosed with gastric cancer (20.1/1000 patient-years). An increased incidence of SPM was observed in patients with GML (standardized incidence ratios [SIR]: 1.71 [1.14-2.45]) compared to the general French population especially for gastric cancer (SIR: 16.1 [5.19-37.56]). This elevated risk of SPM was significantly increased only in patients treated with immuno/chemotherapy but not in patients treated with Helicobacter pylori eradication alone. Long-term follow-up of patients with GML is mandatory even in patients who have achieved complete remission.
Fichier non déposé

Dates et versions

hal-01542978 , version 1 (20-06-2017)

Identifiants

Citer

Aurelien Amiot, Valerie Jooste, Charlotte Gagniere, Michaël Lévy, Christiane Copie-Bergman, et al.. Second primary malignancies in patients treated for gastric mucosa-associated lymphoid tissue lymphoma.. Leukemia & lymphoma, 2017, pp.1-11. ⟨10.1080/10428194.2017.1283033⟩. ⟨hal-01542978⟩
114 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More